Navigation Links
Unilife Granted Key U.S. Patent for Unifill Prefilled Syringe

YORK, Pa., July 9, 2012 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS), today announced that the United States Patent and Trademark Office (USPTO) has granted the Company U.S. Patent No. 8,167,837 for the Unifill® ready-to-fill (prefilled) syringe.

This key Unilife patent, which provides Unilife and its customers with a long-term competitive advantage into 2026, covers Unilife's proprietary technology for the integration of automatic and operator-controlled needle retraction features within the barrel of a prefilled syringe.

Mr. Alan Shortall, CEO of Unilife Corporation, said, "The Unifill syringe is the world's first and only prefilled syringe with integrated safety features. This patented technology differentiates Unifill from every other prefilled syringe that is either on the market, or known by us to be in development. It is a key component of our strong and fast-expanding intellectual property (IP) portfolio. The patent further validates the uniqueness of Unilife's proprietary integrated retraction technology.

"The importance of this patent is evident from the many pharmaceutical companies seeking access to our best-in-class devices.  Unilife's devices enable pharmaceutical companies to differentiate their injectable drugs from competitors' products, build market share and protect or increase their revenues.

"Expert legal opinion indicates that the unique safety, functionality and performance characteristics of our proprietary technologies may be utilized to extend the commercial lifecycles of drug-device combination products beyond the patent expiration of the drug itself. Because more than 70 biologics with combined annual revenues in excess of $70 billion are set to fall off the patent cliff between now and 2020, we have commenced discussions with a number of pharmaceutical customers with a view to enhancing and extending the commercial lifecycles of their blockbuster therapies.

"We continue to invest heavily in the diversification of our IP portfolio in order to expand and protect our position as a global leader for injectable drug delivery systems. Indeed, we expect our total number of patent filings to increase by two to three times in calendar year 2012 compared to 2011. These investments are building significant shareholder value and providing the impetus for our future growth by significantly expanding the scope of commercial opportunities available to Unilife," concluded Mr. Shortall.

Unilife has to-date been granted 60 patents worldwide for its device technologies and has filed more than one hundred additional patent applications that are expected to be granted at various times by the USPTO and other international patent organizations. 

About Unilife CorporationUnilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of advanced drug delivery systems. Unilife collaborates with pharmaceutical and biotechnology companies seeking innovative, differentiated devices that can enable or enhance the delivery of injectable drugs and vaccines supplied in either a liquid stable or lyophilized form. The Unifill syringe, the world's first and only prefilled syringe with fully integrated safety features, sits at the leading edge of this diversified portfolio. In addition to prefilled and hypodermic safety syringes with automatic, user-controlled needle retraction, Unilife has other proprietary technology platforms including drug reconstitution delivery systems, auto-injectors, auto-infusion pump systems and specialized devices for targeted organ delivery. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information on Unilife, please visit www.unilife.comForward-Looking Statements This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission. 

General: UNIS-G Investor Contacts (US):Analyst EnquiriesInvestor Contacts (Australia)Todd Fromer / Garth RussellLynn Pieper

Jeff CarterKCSA Strategic Communications 

Westwicke Partners

Unilife CorporationP: + 1 212-682-6300

P: + 1 415-202-5678

P: + 61 2 8346 6500

SOURCE Unilife Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Unilife Signs Long-Term Supply Contract for the Unifill Prefilled Syringe
2. Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
3. QRxPharma Granted Additional US Patent on MoxDuo®
4. BiO2 Medical Granted CE Mark for the Angel™ Catheter, the First IVC Filter with a Prophylactic Use Indication
5. Broad Patent Protection Granted for iBio Immunomodulator
6. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
7. Frost & Sullivan: European Bipolar Therapeutics Market Slows Down in the Short Term As Key Blockbuster Drugs Go Off Patent
8. Generics in the Antivirals Market to 2018 - Launch of Generic Combivir and Patent Expiry of Sustiva, Kaletra and Epivir-HBV will Drive Volume Growth
9. Improved Maintenance and Control of Electronic Health Records. ICAP Patent Brokerage Announces for Auction Patented Techniques for Improved Patient Control and Selective Access to Electronic Medical Records
10. DataMotion Files Provisional Patent for Technology that Enables Easy and Secure Doctor-Patient Email Interaction
11. World Renowned Inventor, Donald Spector, Develops Patent For Wireless Electric Acupuncture Patches
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015 Building on its ... & Johnson (NYSE: JNJ ) today announced ... Companies to significantly reduce the burden of HIV ... 74 percent of new HIV infections among adolescents ... AIDS Day, these new initiatives include collaborations with ...
(Date:12/1/2015)... 2015 ) ... Equipment and Disposables Market by product, by Animal ... their offering. --> ) has ... and Disposables Market by product, by Animal - ... offering. --> Research and Markets ( ...
(Date:12/1/2015)... CytRx Corporation (NASDAQ: CYTR ), a ... announced that it has reached its enrollment target of ... clinical trial of aldoxorubicin in patients with previously treated ... completed in Q1 2016. The Phase 3 trial is a ... Assessment from the FDA at 79 sites in ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 2015 , ... Speech and physical therapies are traditionally conducted ... and under the right circumstances, these practices can be merged. This combination ... his or her therapeutic sessions, as well as gives the physical and speech ...
(Date:12/1/2015)... ... December 01, 2015 , ... It’s official: Tattoo taboo is a ... number even greater among Millennials (a whopping one in three aged 18 to 25 ... who are dissatisfied with their ink. In fact, RealSelf , the world’s largest ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... everything. That is why Hollister Incorporated has launched the VaPro Plus Pocket™ touch ... product in the VaPro touch free catheter portfolio,” said Michael Gresavage, Vice President ...
(Date:12/1/2015)... Burlington, MA (PRWEB) , ... December 01, 2015 , ... ... the release of Clarity, the latest addition to the devices for sale in the ... technologies, 755 nm Alexandrite and long-pulsed 1064 nm Nd:YAG lasers, into a single platform ...
(Date:12/1/2015)... ... December 01, 2015 , ... With FCPX Overlay: Grit , ... control over customization, the possibilities are truly endless, all with a click of a ... position, vertical flip, horizontal flip, depth of field and more, all within Final Cut ...
Breaking Medicine News(10 mins):